Cossío AJE

Language: Spanish
References: 13
Page: 47-51
PDF size: 57.74 Kb.

ABSTRACT

The most common etiologies for mitral regurgitation (MR) include mitral valve prolapse syndrome, coronary artery disease, infective endocarditis, rheumatic heart disease, collagen vascular disease, and, recently, anoretic drugs have also been reported to cause MR. In chronic severe MR, forward cardiac output is maintained for the development of afterload reduction with increase in compensatory left ventricular (LV) end-diastolic volume and LV ejection fraction. It is well established that some patients with asymptomatic mitral regurgitation develop irreversible contractile dysfunction of the LV, which is often masked by the afterload-reducing effect of the regurgitant flow; cardiologyst have to use some variables, like LV chamber elastance, LV End-Systolic dimensions and volumes, left atrial area combined with ejection fraction, in their clinical evaluations tube able to predict surgery mortality. Careful and periodic evaluation of left ventricular function and size is essential to optimize the timing of surgical intervention in these patients. After symptoms occur, outcome is improved with surgical interventiones compared to medical therapy, with a reported survival of only 45% at 5 years without surgical intervention. Vasodilators, diuretics, and recently, angiotensin receptor antagonists heve been used in MR medical therapy. Long-term carvedilol therapy in patients with chronic heart failure may prevent or partially reverse progressive left ventricular dilatation. Concomitant by, it has been associated with recovery of diastolic reserve and a decrease in mitral regurgitation.

REFERENCES

1. Jones EC, Devereux RB, Roman MJ, Liu JE, Fishman D, Lee ET, et al : Prevalence and Correlates of Mitral Regurgitation in a Population-Based Sample (The Strong Heart Study). Am J Cardiol 2001; 87: 298-304.

2. Braunwald E: Mitral Regurgitation: Physiologic, Clinical and Surgical considerations. N Engl J Med 1969; 281: 425-33.

3. Burwash IG, Blackmore GL, Koilpillai CJ: Usefulness of left atrial and left ventricular chamber sizes as predictors of the severity of mitral regurgitation. Am J Cardiol 1992; 70: 774-79.

4. Wanishawad C, Weathers LB, Puavilai W: Mitral Regurgitation and left atrial thrombus in Rheumatic Mitral Valve Disease: a clinicopathologic study. Chest 1995; 108: 677-81.

5. Braunwald E: Control of Myocardial oxygen consumption: Physiologic and clinical considerations. Am J Cardiol 1971; 27: 416-19.

6. Borow K, Green LH, Mann T: End systolic volumen as a predictor of postoperative left ventricular performance in volumen overload from valvular regurgitation. Am J Med 1980; 68: 655-58.

7. Starling MR: Effects of Valve Surgery on Left Ventricular Contractile Function in patients with long-term Mitral Regurgitation. Circulation 1995; 92: 811-18.

8. Starling MR, Kirsh MM, Montgomery DG, Gross MD: Impaired Left Ventricular Contractile Function in patients with long-term Mitral Regurgitation and normal Ejection Fraction. J Am Coll Cardiol 1993; 22: 239-250.

9. Bonow R, Carabello B, De Leon A, Edmunds HL, Fedderly BJ, Freed MD, et al: ACC/AHA Guidelines for the management of patients with valvular heart disease. J Am Coll Cardiol 1998; 32: 1486-1570.

10. Dujardin KS, Enriquez-Sarano M, Bailey KR, Seward JB, Tajik J: Effect of Losartan on Degree of Mitral Regurgitation Quantified by Echocardiography. Am J Cardiol 2001; 87: 570-76.

11. Copomolla S, Febo O, Gnemmi M, Riccardi G, Opasich C, Caporotondi A, et al: ß-Blockade therapy in choronic heart failure: diastolic function and mitral regurgitation improvement by Carvedilol. Am Heart J 2000; 139: 596-608.

12. Delahaye JP, Gare JP, Viguier E, Delahaye F, de Gevigney G, Milon H: Natural history of Severe Mitral Regurgitation. Eur Hear J 1991; 12(Suppl B): 5-9.

13. Muñoz S, Gallardo J, Díaz Gorrin JR, Medina O: Influence of Surgery on the natural history of Rheumatic Mitral and Aortic Valve Disease. Am J Cardiol 1975; 35: 234-42.